A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG miceon November 29, 2019 at 2:45 am
The clinical scores of peripheral arthritis decreased in the ADA group at 3 weeks after first adalimumab injection. Using positron emission tomography–magnetic resonance imaging and histologic ...
- Cannabis and Rheumatoid Arthritis: Symptom Relief Clear -- Underlying Benefits Less Certainon November 29, 2019 at 12:04 am
However, the future of their role in chronic inflammation remains bright. Full Critique As laws and attitudes change regarding medical cannabis, more clinicians and patients view the plant and its ...
- Inflammatory Markers Market Will Reflect Significant Growth Prospects during 2019-2029on November 28, 2019 at 11:53 pm
C reactive protein and interleukin are the most common form of inflammatory markers. Some of the common inflammatory conditions include rheumatoid arthritis, tissue injury and burns, Crohn’s disease, ...
- These Are the Best Supplements for People Living with Arthritison November 26, 2019 at 4:05 pm
You're not alone. To help you navigate the slew of products currently on the market, we tapped Dr. Susan Blum, author of Healing Arthritis ($18.99, amazon.com) and founder of BlumHealth MD, to help us ...
- Let's Talk About Rheumatoid Arthritis Treatmenton November 25, 2019 at 3:17 pm
Let's refresh: Rheumatoid arthritis is an autoimmune disease, which means the immune system turns its sights on healthy tissue in the body, causing inflammation. This form of arthritis targets the ...
- Can Changing the Foods You Eat Really Reduce Inflammation in Your Body?on November 25, 2019 at 8:26 am
In today's health-conscious world, inflammation is something of a buzz word. You've likely heard that consuming turmeric (a source of curcumin) is helpful for those suffering from joint pain or ...
- Let's Talk About the Symptoms of Rheumatoid Arthritison November 24, 2019 at 10:43 am
Rheumatoid arthritis is an autoimmune disease, which means the immune system mistakenly attacks healthy tissue in the body, causing inflammation. In the case of RA, the target is the synovial membrane ...
- An Anti-Inflammatory Diet Can Improve RA Symptoms in Just Two Weeks, New Research Suggestson November 22, 2019 at 8:18 pm
There’s growing interest and evidence to suggest that dietary changes can improve symptoms and inflammatory markers in people with rheumatoid arthritis (RA). Many arthritis clinics now routinely ...
- How Keeping a Symptom Diary Can Help You Manage Inflammatory Back Painon November 22, 2019 at 9:10 am
Like other spondyloarthropathies, IBP, which is also called spondyloarthritis, is actually a form of inflammatory arthritis. This means the pain and discomfort you feel with IBP results from the cells ...
via Bing News